Drug discovery startup GTN lands £2.1m Seed from Octopus Ventures

May 4, 2018 · uktech.news

Noornew2 898x505

London-based startup GTN has raised £2.1m in Seed funding in a round led by Octopus Ventures to transform drug discovery.

Pentech and existing investor Entrepreneur First also contributed to the round, which will be used to build on GTN’s drug discovery technology.

On average, bringing a new drug to the market costs $2.9bn and takes 15 years, with a high chance of failure; plus an expected 50% drop in R&D output every nine years.

GTN, a female-led company, has developed a technology called Generative Tensorial Networks. It combines and builds upon techniques from machine learning and quantum physics to simulate, filter and discover new molecules. The company says this will help bring efficiencies to the drug development cycle, discovering much-needed medicines for patients with cancer, autoimmune and infectious diseases.

Read Complete Article

RT @thelovelysteve: Delighted to announce this partnership with @join_ef to give their #biotech & #healthtech startups a competitive edge!…

This #LondonHistorySchoolsDay primary school students dressed up as their favourite Londoners to help bring our cit… https://t.co/ubms8WHttW

Can you successfully navigate your way through a cyber security attack? Choose the course of action to take in resp… https://t.co/YBVoaWfx7P

Hackers are scanning for MySQL servers to deploy GandCrab ransomware https://t.co/YanQYTBunh

You may have assumed that petrol was his passion and farming just a pose. But Jeremy Clarkson is so smitten by the… https://t.co/p52E9LFGLv

More in London